TP53 and osteosarcoma: Noteworthy, doxorubicin, an anticancer drug commonly used in osteosarcoma therapy, has been previously shown to induce intracellular ROS formation, which was found necessary for mitochondrial membrane depolarization, pro-caspase 3 activation, apoptosis and G2/M phase arrest in the p53-null SaOS-2 osteosarcoma cell line [52].